UBS keeps Buy on Vertex and SI-BONE, lifts both price targets
UBS kept Buy ratings on Vertex Pharmaceuticals and SI-BONE and raised their price targets to $640 and $26. Source: TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
UBS analysts kept their Buy rating on Vertex Pharmaceuticals and raised the price target from $615 to $640, a 4.1% increase. According to TradingView, the new target implies upside of 15.7% from the November 2 close of $553.15.
For SI-BONE, UBS also retained its Buy rating and lifted its target from $25 to $26, a 4.0% increase. That target implies roughly 28.6% upside from the November 2 close of $20.22.
why it matters
Broker updates like these appear regularly and rarely move the broader market on their own, but they show how sell-side analysts view these stocks. Per Benzinga data, the five latest Vertex notes carry targets between $563 and $650, while the latest three SI-BONE notes range from $23 to $26. This is not investment advice.
tags
instruments
sources
- UBS maintains Vertex Pharmaceuticals at Buy, raises price target to $640 from $615 — TradingView, 3 November 2026 at 16:13 UTC
- UBS maintains SI-BONE at Buy, raises price target to $26 from $25 — TradingView, 3 November 2026 at 16:10 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗